MedTrace Logo

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

NCT04599062 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2026-01-29

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to determine the safety and tolerability of talimogene laherparepvec when combined with radiation therapy.

Approximately 46 people will take part in this study conducted by investigators at the University of Iowa.

Conditions

  • Soft Tissue Sarcoma

Interventions

DRUG

Talimogene Laherparepvec

Talimogene Laherparepvec

RADIATION

Radiotherapy

Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • John Rieth

    lead OTHER

Principal Investigators

  • John Rieth, MD · University of Iowa Holden Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-10
Primary Completion
2023-02-07
Completion
2028-02-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04599062 on ClinicalTrials.gov